Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ACRS stock hub

Aclaris Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ACRSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

688.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ACRS

In the news

Latest news · ACRS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-48.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-33.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ACRS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

188

Groups with data

Currency

USD

Showing 188 of 188 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001557746
Company name	Aclaris Therapeutics, Inc.
Country	United States
Country code	US
Cusip	00461U105
Employees	73
Employees Change	9%
Employees Change Percent	14.06
Enterprise value	$499.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-10-07
Isin	US00461U1051
Last refreshed	2026-05-10
Market cap	$688.5M
Market cap category	Small-Cap
Price	$4.93
Price currency	USD
Rev Per Employee	114,616.44x
Sector	Healthcare
Sic	2834
Symbol	ACRS
Website	https://www.aclaristx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10.12%
EV Sales Forward	98.63x
EV/Sales	59.73x
P/B ratio	5.76x
P/S ratio	82.29x
PS Forward	135.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-55.9M
Net Income	$-69.7M
Net Income Growth Years	1%
Pretax Margin	-832.58%
Profit Per Employee	$-954,274
ROA	-24.72
Roa5y	-23.63
ROCE	-45.8
ROE	-48.42
Roe5y	-61.18
ROIC	-33.58

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-13.37%
Cagr1y	294.77%
Cagr3y	-18.11%
Cagr5y	-26.48%
EPS Growth Years	1
Revenue Growth	-52.93x
Revenue Growth Q	37.18x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	-35.25x
Revenue Growth5 Y	4.08x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.04
Assets	$198.7M
Cash	$105.4M
Debt	$2M
Debt Equity	$0.01
Equity	$143.6M
Liabilities	$55.1M
Net Cash	$188.8M
Net Cash By Market Cap	$27.42
Net Cash Growth	-20.63%
Net Debt Equity	$-1.31
Tangible Book Value	$143.6M
Tangible Book Value Per Share	$1.03
WACC	8.5

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.03
Net Working Capital	$-22M
Quick ratio	4.03
Working Capital	$82.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-37.77%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-76.2%
1Y total return	294.4%
200-day SMA	2.85
3Y total return	-45.1%
50-day SMA	3.89
50-day SMA vs 200-day SMA	50over200
5Y total return	-78.52%
All Time High	33.88
All Time High Change	-85.45%
All Time High Date	2015-12-17
All Time Low	0.59
All Time Low Change	735.31%
All Time Low Date	2023-11-13
ATR	0.26
Beta	0.78
Beta1y	0.93
Beta2y	1.57
Ch YTD	63.79
High	4.94
High52	4.94
High52 Date	2026-05-08
High52ch	-0.2%
Low	4.66
Low52	1.16
Low52 Date	2025-05-15
Low52ch	325%
Ma50ch	26.61%
Price vs 200-day SMA	73.1%
RSI	68.69
RSI Monthly	59.05
RSI Weekly	70.83
Sharpe ratio	1.79x
Sortino ratio	4.13
Total Return	-37.77%
Tr YTD	63.79
Tr1m	31.47%
Tr1w	11.79%
Tr3m	38.1%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	2
Analyst Price Target Top	$11
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.16
Earnings Revenue Estimate	1,331,336x
Earnings Revenue Estimate Growth	-8.5x
Operating Income	$-78.5M
Operating margin	-938
Price target	$11.33
Price Target Change	$130
Price Target Change Top	$123

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	96,690,016%
Float Percent	69.23%
Shares Insiders	2.26%
Shares Institutions	43.57%
Shares Out	139,663,680
Shares Qo Q	5.01%
Shares Yo Y	37.77%
Short Float	7.32%
Short Ratio	4.34
Short Shares	5.07

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,399,614.75x
Bv Per Share	1.03
CAPEX	$-81,000
Ch10y	-76.2
Ch1m	31.47
Ch1w	11.79
Ch1y	294.4
Ch3m	38.1
Ch3y	-45.1
Ch5y	-78.52
Ch6m	112.5
Change	1.44%
Change From Open	2.07
Close	4.86
Days Gap	-0.62
Dollar Volume	5,944,179.9
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-78.5M
EBITDA	$-78.5M
EPS	$-0.56
F Score	1
Financing CF	52,194,000
Fiscal Year End	December
Founded	2,012
Investing CF	-1,686,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	3.19
Ma150ch	54.35%
Ma20	4.37
Ma20ch	12.89%
Net CF	-1,697,000
Next Earnings Date	2026-08-06
Open	4.83
Optionable	Yes
Position In Range	96.43
Post Close	4.93
Postmarket Change Percent	0.41
Postmarket Price	$4.95
Price Date	2026-05-08
Ptbv Ratio	4.79
Relative Volume	0.86x
Revenue	8,367,000x
SBC By Revenue	143.98x
Share Based Comp	12,047,000
Tr6m	112.5%
Us State	Pennsylvania
Volume	1,205,716
Z Score	-4.98

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ACRS pay a dividend?

Capital-return profile for this ticker.

Performance

ACRS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ACRS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+43.6%

Float: +69.2% of shares outstanding

Insider ownership

+2.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ACRS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

68.7

Neutral momentum band

Price vs 200-day MA

+73.1%

50/200-day relationship not available

Beta (5Y)

0.78

Less volatile than the market

Sharpe ratio

1.78

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ACRS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ACRS stock rating?

Aclaris Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ACRS analysis?

The full report lives at /stocks/ACRS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ACRS?

The latest report frames ACRS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ACRS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.